HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

506.075

-10.940-2.12%

Number of Gainers:9

Number of Losers:21

Number of Flat:3

PE:- -

High:516.490

Open:516.490

Low:500.597

Close:517.015

Volume:149.97M

Turnover:4.87B

Market Cap:324.25B

Float Cap:288.12B

Loading ...

BIODLINK-B Posts Interim Results with Total Revenue of RMB 246 Million, CDMO Segment Surges While Proprietary Pipeline Accelerates Global Expansion

TOT Biopharm FY26 H1 Net Loss Swings to RMB 59 Million; Revenue Drops 49.7% to RMB 246 Million

China's Henlius H1 Revenue Jumps on Drug Sales, License Income

Hua Medicine Grants 200,000 Share Options at HK$ 2.6 Each

Antengene-B Turns Profitable in First Half with Net Income of RMB216 Million

Biotech Firm Antengene's H1 Revenue Jumps on Licensing Deals

Henan Chemical Firm Commits 38 Million Yuan to Revamp Pharmaceutical Intermediate Facility

Antengene FY26 H1 Returns to Profit at RMB 216.35 Million; Revenue More than Doubled to RMB 513.08 Million

Antengene Corporation H1 Net Income Attributable RMB 216.3 Million

THOMSON REUTERS

China's Jinxin Fertility Group Interim Revenue Rises on U.S. IVF Demand

Guizhou Unveils 13 Typical Cases of Consumer Rights Violations in Market Regulation Crackdown

AH Share Premium Tracker | August 21 Market Close

Citi Raises Keymed Bio's Target Price to HK$97.5, Maintains Buy/High-Risk Rating

CStone Pharmaceuticals' Application for Tumor Drug Gets China Nod in 23 Days

MT Newswires Live

Market Close Report | ChiNext Gains 1.43% to Lead, Gold Stocks Surge While Agriculture and Pharma Decline

Medical sector compliance cracks widen as military procurement probes hit major drugmakers

Huiyu Pharma's Aesthetic Medicine Expansion Stalls: Subsidiary Insolvency and Funding Model Expose Multiple Hazards

Norway's Medistim Q2 Revenue Rises on Own-Product Sales Growth

Akeso Says China NMPA Clears Phase I Trial for B7-H3 ADC Ak157d1 in Solid Tumors

Akeso's Ak157d1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/BK1574/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":506.0749,"timestamp":1787299686774,"preClose":517.0147,"halted":0,"volume":149966252,"delay":0,"changeRate":-0.02116,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-10.939819,"latestTime":"08-21 16:00:00","open":516.49023,"high":516.49023,"low":500.59692,"amount":4865243342.5,"amplitude":0.030741,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"pbRate":4.109535,"peRate":-81.157718,"turnoverRate":0.005372,"increases":11,"decrements":20,"flats":2,"marketCap":324245256080,"floatMarketCap":288118014384},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":516.49023,"amplitude":0.030741,"preClose":517.0147,"low":500.59692,"pbRate":"4.109535","latestPrice":506.0749,"volume":149966252,"delay":0,"open":516.49023,"prevYearClose":556.26263,"prevWeekClose":518.327,"prevMonthClose":473.313,"prevQuarterClose":453.519,"fiveDayClose":518.327,"twentyDayClose":498.407,"sixtyDayClose":542.586,"secType":"PLATE","market":"HK","turnoverRate":0.005372,"peRate":-81.157718,"marketCap":324245256080,"floatMarketCap":288118014384,"timestamp":1787299686774,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":9,"down":21,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1191189592","title":"BIODLINK-B Posts Interim Results with Total Revenue of RMB 246 Million, CDMO Segment Surges While Proprietary Pipeline Accelerates Global Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1191189592","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191189592?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:00","pubTimestamp":1787313625,"startTime":"0","endTime":"0","summary":"BIODLINK-B (01875) has announced its interim results for the six months ended June 30, 2026, revealing robust growth across its contract development and manufacturing organization (CDMO) segment...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CDMO","BK1574","01875","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260315","title":"TOT Biopharm FY26 H1 Net Loss Swings to RMB 59 Million; Revenue Drops 49.7% to RMB 246 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260315","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661260315?lang=en_us&edition=fundamental","pubTime":"2026-08-21 19:47","pubTimestamp":1787312862,"startTime":"0","endTime":"0","summary":"TOT Biopharm FY26 H1 net loss swings to RMB 59 million; revenue drops 49.7% to RMB 246 millionTOT BioPharm posted a net loss of RMB 59 million for the six months ended June 30, swinging from profit.Re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL4m4SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","SG9999002463.SGD","LU1688375341.USD","LU0039217434.USD","LU0051755006.USD","01875","LU0348825331.USD","LU0516422366.SGD","IE00B0JY6N72.USD","LU3063872942.SGD","LU0128526141.USD","LU1242518931.SGD","LU1880383366.USD","BK1521","BK1576","LU0417516738.SGD","LU0043850808.USD","LU0456846285.SGD","LU0823426480.USD","LU0819121731.USD","LU0181495838.USD","LU0326950275.SGD","LU0516422440.USD","LU0516423091.SGD","LU0359202008.SGD","LU0320764599.SGD","BK1589","LU0029874061.USD","LU0417516902.SGD","SG9999002562.SGD","LU0823426308.USD","LU1242518857.USD","LU0307460666.USD","LU1720050803.USD","LU0359201612.USD","LU0516422952.EUR","LU0979878070.USD","02269","BK1161","LU0052750758.USD","LU0140636845.USD","LU0456827905.SGD","LU0516423174.USD","KURE","LU0856984785.SGD","LU1794554557.SGD","BK1574","LU0348735423.USD","LU0327786744.USD","LU0572944931.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661267758","title":"China's Henlius H1 Revenue Jumps on Drug Sales, License Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2661267758","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661267758?lang=en_us&edition=fundamental","pubTime":"2026-08-21 19:36","pubTimestamp":1787312209,"startTime":"0","endTime":"0","summary":"China's Henlius H1 revenue jumps on drug sales, license incomeOverviewChina biopharma firm's interim revenue rose 27% yr/yr, driven by drug sales and licensingCompany expanded global footprint with ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL1N44I0BX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656","HK0000306685.HKD","02696","BK1191","HK0000165453.HKD","HK0000306701.USD","06996","06855","HK0000320223.HKD","BK1230","BK1583","BK1574","HK0000320264.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661267732","title":"Hua Medicine Grants 200,000 Share Options at HK$ 2.6 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2661267732","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661267732?lang=en_us&edition=fundamental","pubTime":"2026-08-21 19:36","pubTimestamp":1787312167,"startTime":"0","endTime":"0","summary":"Hua Medicine grants 200,000 share options at HK$ 2.6 eachHua Medicine granted 200,000 share options to an employee under its share option scheme on Aug. 21, 2026.Exercise price set at HK$ 2.6 per shar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL8zj6Md:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02552","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122991385","title":"Antengene-B Turns Profitable in First Half with Net Income of RMB216 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1122991385","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122991385?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:46","pubTimestamp":1787309190,"startTime":"0","endTime":"0","summary":"Antengene-B (06996) has reported a strong turnaround in its interim results for the six months ended June 30, 2026, achieving a net profit of RMB216 million compared to a loss in the prior year...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","BK1191","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661264711","title":"Biotech Firm Antengene's H1 Revenue Jumps on Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2661264711","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661264711?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:38","pubTimestamp":1787308735,"startTime":"0","endTime":"0","summary":"Biotech firm Antengene's H1 revenue jumps on licensing dealsOverviewBiotech company's H1 revenue rose sharply on licensing deals with UCB, K2 TherapeuticsCompany swung to H1 net profit from loss a yea","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL1N44I0AK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","BK1587","06996","06855","BK1574","BK1161","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143378344","title":"Henan Chemical Firm Commits 38 Million Yuan to Revamp Pharmaceutical Intermediate Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=1143378344","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143378344?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:31","pubTimestamp":1787308286,"startTime":"0","endTime":"0","summary":"A renovation project for a pharmaceutical intermediate production line in Henan Province has entered its second public review phase, with the developer planning a total investment of 38 million...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","159938","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661264647","title":"Antengene FY26 H1 Returns to Profit at RMB 216.35 Million; Revenue More than Doubled to RMB 513.08 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661264647","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661264647?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:27","pubTimestamp":1787308044,"startTime":"0","endTime":"0","summary":"Antengene FY26 H1 returns to profit at RMB 216.35 million; revenue more than doubled to RMB 513.08 millionAntengene posted IFRS revenue of RMB 513.08 million, up RMB 459.9 million, for the six months ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL22M2ss:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996","BK1574","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661326464","title":"Antengene Corporation H1 Net Income Attributable RMB 216.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661326464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661326464?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:27","pubTimestamp":1787308040,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nPLXC5NLS0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1574","06996","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661264564","title":"China's Jinxin Fertility Group Interim Revenue Rises on U.S. IVF Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2661264564","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661264564?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:23","pubTimestamp":1787307829,"startTime":"0","endTime":"0","summary":"China's Jinxin Fertility Group interim revenue rises on U.S. IVF demandOverviewChina fertility clinic operator's interim revenue for six months to June 30 grew 6.6% yr/yrNet profit for the six months ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL1N44I0A0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1219","BK1597","BK1583","01951","BK1587","BK1100","02190","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151570295","title":"Guizhou Unveils 13 Typical Cases of Consumer Rights Violations in Market Regulation Crackdown","url":"https://stock-news.laohu8.com/highlight/detail?id=1151570295","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151570295?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:52","pubTimestamp":1787302339,"startTime":"0","endTime":"0","summary":"In recent years, market regulatory authorities in Guizhou Province have continuously carried out the \"Guardian of Consumption\" enforcement campaign, cracking down on illegal activities that have...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HART","AGNG","GDOC","BK1100","PTH","BK1574","09996","MDEV","IEIH","MEDX","BK1583","LGHT","RSPH","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179668361","title":"AH Share Premium Tracker | August 21 Market Close","url":"https://stock-news.laohu8.com/highlight/detail?id=1179668361","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179668361?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:21","pubTimestamp":1787300495,"startTime":"0","endTime":"0","summary":"As of the August 21 market close, the latest AH premium rankings reveal notable divergences between dual-listed stocks on the Hong Kong and mainland exchanges. NE ELECTRIC (00042), ZHEJIANG SHIBAO...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266512473.USD","LU1008478684.HKD","LU2008162690.USD","IE0008369823.USD","LU0449515922.USD","399300","LU0348788117.USD","LU1831875114.USD","LU0791591158.USD","LU0823426308.USD","BK1562","LU0315179316.USD","LU0708995583.HKD","BK1574","BK1231","BK1552","02768","LU0509642566.USD","BK1122","LU0501845795.SGD","LU0871576103.HKD","BK1166","HK0000252152.HKD","LU0096374516.USD","LU0269904917.USD","LU0210526637.USD","LU1152091754.HKD","LU0417516902.SGD","LU2394011477.USD","03328","LU1481107354.HKD","LU0329678170.USD","HK0000306701.USD","LU2476274720.SGD","LU1064131003.USD","LU0214875030.USD","LU0531971595.HKD","00042","LU0737861772.HKD","LU0737861699.HKD","LU0039217434.USD","LU2148510915.USD","02691","BK1191","SG9999001226.SGD","LU2264538146.SGD","LU0327786744.USD","LU0797268264.HKD","LU0588546209.SGD","HK0001040143.USD","02338","LU1328277881.USD","BK1116","LU0254981946.USD","LU0456846285.SGD","00895","BK1522","LU0348814723.USD","LU0266512127.USD","06745","LU0128522157.USD","SGXZ49509284.SGD","LU0540923850.HKD","LU1303224171.USD","LU0228659784.USD","LU2039709279.SGD","LU1961090484.USD","LU0117841782.USD","LU0862451753.SGD","LU1242518931.SGD","BK1240","IE00B543WZ88.USD","LU1688375341.USD","LU0067412154.USD","LU0823426480.USD","SG9999014674.SGD","01812","HK0000320223.HKD","LU0880133367.SGD","BK1515","01033","LU0348766576.USD","LU1769817096.USD","LU2097828805.USD","IE00BZ08YT58.USD","LU2097828631.EUR","LU1244550221.USD","EWH","LU0173614495.USD","LU0140636845.USD","LU1242518857.USD","BK1144","LU0052750758.USD","LU1282648689.USD","IE0032431581.USD","BK1546","LU3063872942.SGD","BK1507","LU0543330566.HKD","LU0106959298.USD","BK1249","LU0979878070.USD","LU1807302812.USD","LU2097828557.USD","LU0572944931.SGD","03678","LU1224709979.USD","LU2097828714.EUR","LU0348805143.USD","LU1675838814.USD","LU0061477393.USD","00300","LU0868486357.SGD","BK1183","LU0106252389.USD","LU1152091168.USD","LU1282649141.HKD","IE00BZ08YR35.GBP","LU2045819591.USD","IE00B031HY20.USD","BK1147","BK1161","BK1523","LU0051755006.USD","LU0165289439.USD","83130","IE00B29SXG58.USD","IE00B0169L03.USD","BK1526","BK1521","LU0417516738.SGD","02218","LU0531970944.HKD","00638","IE00BMCWC346.EUR","BK1610","LU2125910500.SGD","LU2778985437.USD","BK1607","LU0345780521.USD","BK1110","LU0149721374.USD","LU1188198961.HKD","LU1244550494.USD","688981","LU1023057109.AUD","BK1537","LU1880383440.USD","LU0054450605.USD","01349","06869","IE0034224299.USD","LU0828237510.HKD","LU1960683339.HKD","00553","IE0031814852.USD","BK1558","LU0502904849.HKD","LU0348767384.USD","LU1993786604.SGD","LU0228367735.SGD","LU0244354667.USD","LU0329678337.USD","LU1251922891.USD","02827","07233","LU1282649810.SGD","LU0561508036.HKD","IE00BVYPNP33.GBP","LU0516422366.SGD","00981","BK0214","LU0589944569.HKD","BK1202","BK1506","HK0000352382.USD","LU0607220059.USD","BK1533","LU0163747925.USD","IE0008368742.USD","SG9999004220.SGD","LU0488056044.USD","LU0469268626.HKD","LU1770034418.SGD","LU1794554557.SGD","BK1614","LU0348825331.USD","LU0348816934.USD","BK1214","BK1209","LU1720050803.USD","LU0049853897.USD","LU0516423174.USD","LU0672654166.SGD","IE00BZ08YS42.EUR","BK1154","BK1190","BK1503","LU1813983027.USD","LU0348735423.USD","LU0048580855.USD","02846","00568","LU2399975544.HKD","LU1048596156.SGD","SG9999001093.SGD","LU1504937902.USD","BK1583","LU0326950275.SGD","00956","LU0823040885.USD","06185","BK1576","03188","LU1105468828.SGD","BK1170","LU0828237940.HKD","BK1198","03130","LU0455707207.USD","SG9999002828.SGD","IE00B3M56506.USD","HK0000320264.USD","LU1880383366.USD","LU0307460666.USD","159982","LU0463099449.HKD","03296","LU0072913022.USD","03200","BK1171","LU0516423091.SGD","LU0029875118.USD","IE00BYV24P56.USD","BK1592","SG9999011746.SGD","BK1149","BK1163","LU0640798160.USD","LU0918141887.USD","LU0516422440.USD","02692","03308","BK1560","LU0620787316.HKD","HK0000252160.HKD","02899","LU1064130708.USD","LU0314109678.HKD","HK0000352291.HKD","HK0000500386.USD","BK1105","LU1282649067.USD","BK1140","LU1064131342.USD","LU1769817179.HKD","LU1046422090.SGD","LU0149534421.HKD","IE00BF5LJ272.USD","LU0516422952.EUR","LU1244550577.SGD","LU0456827905.SGD","SG9999002463.SGD","LU2476274308.USD","BK1554","01989","BK1237","BK1141","03986","BK1514","IE00B031J352.USD","IE00BVYPNQ40.USD","LU2226246903.HKD","LU0082770016.SGD","BK1564","BK1544","LU0370786039.SGD","LU0648948544.HKD","LU2242644610.SGD","01108","LU0164939612.USD","HK0000306685.HKD","LU0918141705.HKD","LU0164880469.USD","IE00B5MMRT66.SGD","LU1226287529.USD","LU0348827113.USD","LU0384037296.USD","LU0821914370.USD","83188","03968","LU1366334651.USD","LU0543330483.HKD","LU0359201612.USD","BK1594","LU0211977185.USD","LU0886674414.USD","09989","LU0287142896.SGD","LU0634319403.HKD","03143","LU0456854461.SGD","LU2097828474.EUR","LU1115378108.SGD","LU0359202008.SGD","LU0229945570.USD","02475","LU0043850808.USD","LU2294711473.HKD","LU0320764599.SGD","LU0164865239.USD","LU0791590937.USD","LU0890818403.SGD","LU1211504680.USD","02359","LU0449509016.USD","01057","LU0593848301.USD","LU0320764755.SGD","BK1193","LU1719994722.HKD","IE00BGHQDM52.EUR","LU2177674079.SGD","BK1223","BK1505","03759","00916","SGXZ81163826.USD","LU0431992006.USD","LU0345780281.USD","LU0328353924.USD","LU0359201885.HKD","HK0001040168.HKD","LU0181495838.USD","LU0231483743.USD","03750","SG9999006597.SGD","BK1551","LU1988902786.USD","LU1366334578.USD","82846","LU0082770016.USD","LU1808992512.USD","LU0828238088.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162184322","title":"Citi Raises Keymed Bio's Target Price to HK$97.5, Maintains Buy/High-Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1162184322","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162184322?lang=en_us&edition=fundamental","pubTime":"2026-08-21 15:54","pubTimestamp":1787298869,"startTime":"0","endTime":"0","summary":"Citi has released a research report highlighting that KEYMED BIO-B (02162) posted first-half 2026 revenue of RMB617 million, marking a 24% year-over-year increase. Notably, sales of stapokibart...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1074936037.SGD","LU1366192091.USD","LU0098860793.USD","LU0170899867.USD","LU0162691827.USD","LU0477156953.USD","LU0320765646.SGD","LU0106831901.USD","BK4207","LU2125154778.USD","EWH","LU1201861249.SGD","LU2462157665.USD","LU1162221912.USD","LU1244550221.USD","LU1791807156.HKD","LU1267930227.SGD","LU0648001328.SGD","LU2417539215.USD","LU0128525689.USD","LU0314106906.USD","LU1144417596.USD","BK1161","02162","LU1668664300.SGD","LU2236285917.USD","BK4566","LU0130517989.USD","LU1244550494.USD","LU0203347892.USD","LU0130102774.USD","LU0052756011.USD","LU2456880835.USD","IE00BSNM7G36.USD","C","IYF","BK1583","FTXO","LU2125154935.USD","BK1574","LU2360032135.SGD","BK4504","LU0203345920.USD","TFNS","BK1587","LU1244550577.SGD","BK4534","LU0980610538.SGD","LU0072461881.USD","LU1506573853.SGD","BK4559","LU0310800965.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661684172","title":"CStone Pharmaceuticals' Application for Tumor Drug Gets China Nod in 23 Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2661684172","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661684172?lang=en_us&edition=fundamental","pubTime":"2026-08-21 15:43","pubTimestamp":1787298214,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals'  investigational new drug application for CS5007 was rapidly approved by China's National Medical Products Administration in 23 days.The global multicenter phase I study of the tumor drug began in Australia in June, with the first patient successfully enrolled, and will be conducted in parallel in China, according to a Friday Hong Kong bourse filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1574","02616","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172894321","title":"Market Close Report | ChiNext Gains 1.43% to Lead, Gold Stocks Surge While Agriculture and Pharma Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=1172894321","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172894321?lang=en_us&edition=fundamental","pubTime":"2026-08-21 15:40","pubTimestamp":1787298041,"startTime":"0","endTime":"0","summary":"On August 21, the three major A-share indices closed higher, with the ChiNext Index leading the gains. The Shanghai Composite Index edged up 0.04% to 3,905.20 points, the Shenzhen Component Index...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["399006","399001","399300","03147","83130","03188","159982","03130","02827","BK1147","09939","BK1515","159562","159041","BK1574","83188","82846","159938","BK1161","GLDW","07234","07233","02846"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112242259","title":"Medical sector compliance cracks widen as military procurement probes hit major drugmakers","url":"https://stock-news.laohu8.com/highlight/detail?id=1112242259","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112242259?lang=en_us&edition=fundamental","pubTime":"2026-08-21 15:01","pubTimestamp":1787295676,"startTime":"0","endTime":"0","summary":"A recent penalty announcement from the military procurement website has thrust Yuyue Medical into the public spotlight, with its core wholly-owned subsidiary suspended from military purchasing...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1161","09939","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170961908","title":"Huiyu Pharma's Aesthetic Medicine Expansion Stalls: Subsidiary Insolvency and Funding Model Expose Multiple Hazards","url":"https://stock-news.laohu8.com/highlight/detail?id=1170961908","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170961908?lang=en_us&edition=fundamental","pubTime":"2026-08-21 14:52","pubTimestamp":1787295166,"startTime":"0","endTime":"0","summary":"Under the pressure of generic drug centralized procurement, Huiyu Pharmaceutical (688553.SH) has pinned hopes on the aesthetic medicine sector to forge a second growth curve. Yet its aesthetic...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661825746","title":"Norway's Medistim Q2 Revenue Rises on Own-Product Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2661825746","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661825746?lang=en_us&edition=fundamental","pubTime":"2026-08-21 14:40","pubTimestamp":1787294458,"startTime":"0","endTime":"0","summary":"Norway's Medistim Q2 revenue rises on own-product sales growthOverviewNorway medical device maker's Q2 revenue grew 19.5% yr/yr to NOK 202 mlnQ2 operating profit (EBIT) rose 20.6% to NOK 65.3 mln, EBI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL1N44I05U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1574","02190","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661528902","title":"Akeso Says China NMPA Clears Phase I Trial for B7-H3 ADC Ak157d1 in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2661528902","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661528902?lang=en_us&edition=fundamental","pubTime":"2026-08-21 13:31","pubTimestamp":1787290275,"startTime":"0","endTime":"0","summary":"Akeso says China NMPA clears Phase I trial for B7-H3 ADC AK157D1 in solid tumorsAkeso secured China NMPA CDE clearance to start a Phase I trial of AK157D1, a B7-H3 antibody-drug conjugate, in advanced","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDLc1jnKH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","LU2488822045.USD","LU1794554557.SGD","LU1720050803.USD","LU0417516571.SGD","LU0348735423.USD","LU0634319403.HKD","LU0348767384.USD","09926","LU0348783233.USD","LU0417516902.SGD","LU0348827113.USD","LU2778985437.USD","BK1574","LU0417516738.SGD","IE00BPRC5H50.USD","LU0540923850.HKD","LU0348825331.USD","KURE","IE00B5MMRT66.SGD","LU0348766576.USD","LU2399975544.HKD","LU0348784397.USD","LU2476274720.SGD","LU0561508036.HKD","LU2476274308.USD","IE00B543WZ88.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661252887","title":"Akeso's Ak157d1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2661252887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661252887?lang=en_us&edition=fundamental","pubTime":"2026-08-21 13:30","pubTimestamp":1787290258,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nTUA6ZY0XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0417516738.SGD","LU0634319403.HKD","LU0348767384.USD","LU0417516571.SGD","LU0348735423.USD","KURE","LU0348783233.USD","LU2778985437.USD","LU1961090484.USD","LU2476274720.SGD","LU2488822045.USD","LU0540923850.HKD","LU1794554557.SGD","09926","LU2399975544.HKD","LU0348766576.USD","LU0417516902.SGD","IE00B5MMRT66.SGD","LU0561508036.HKD","LU1720050803.USD","LU0348827113.USD","BK1574","LU0348784397.USD","IE00BPRC5H50.USD","IE00B543WZ88.USD","BK1161","LU0348825331.USD","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":2,"totalSize":286,"code":"91000000","status":"200"}]}}